News Release Details
News Release Details
Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy Science
Study Conducted in Association with
Jaguar Plans to Launch the Prophylactic Formulation of Neonorm Calf this Year in Powder Form for Administration in Liquid
Neonorm™ Calf, one of Jaguar’s lead non-prescription products, has been formulated and clinically tested to help proactively retain fluid in dairy calves and reduce the severity of diarrhea—aiding the animals in avoiding debilitating, dangerous levels of dehydration associated with scours. The powder form of the product allows for ease of administration for herd-wide management.
The objectives of this study were to evaluate the prophylactic use of SB-300, the standardized botanical extract in Neonorm™ Calf, on reducing fecal water loss and diarrhea events in Holstein bull calves individually housed under a restricted whole-milk feeding regimen (6 liters/day) from 1 to 25 days of life.
A double-blinded randomized clinical trial was designed to allocate a total of 40 newborn calves into 1 of 2 treatment groups: 20 calves received (twice daily) a solution containing 500 mg of SB-300 added to whole milk for the first 15 days of life, and the other 20 calves received sterile water added to whole milk for the same period. Treatment solutions had a total volume of 10 mL per treatment. Data regarding fecal dry matter were collected to precisely measure water content in fecal samples and to define diarrhea events.
The group treated with SB-300 had significantly increased fecal dry matter during the study period compared with calves in the control group. Additionally, significantly fewer events of diarrhea were observed for calves in the group treated with SB-300 (16.9%) compared with calves in the control group (46.5%). Dehydration status was evaluated and treated accordingly; calves with moderate dehydration were offered oral electrolytes, and calves with severe dehydration were rescued with intravenous fluid therapy. Calves in the SB-300 group had fewer intravenous fluid therapies administered during the study period (1.6%) compared with the control group (3.1%). Overall fluid therapy administered (oral electrolytes plus intravenous fluids) was significantly higher for the control group (9.2%) compared with the SB-300 group (6.1%) during the study period.
“These results suggest that 500 mg of SB-300 added to the milk for 15
days can reduce the incidence of diarrhea and reduce severe dehydration
in milk-fed calves,” stated Dr.
The study results complement the results of a prior study, also
conducted by Jaguar in association with
Additionally, the positive prophylactic effect of the powder formulation
of Neonorm™ in calves supports and underscores the
prophylaxis data generated by the piglet studies of the powder
formulation of Neonorm™ conducted in 2016 in
“The standardized botanical extract in Neonorm™ Calf is
sustainably derived from the Amazonian tree species, Croton lechleri,
and has a rich history of medicinal use by indigenous peoples in the
Northwestern Amazon rainforests of South America,” commented Dr.
Neonatal calf diarrhea is a multifactorial disease that can be caused by
infectious and noninfectious factors. In a report from the
As announced last week, Jaguar has entered into a binding agreement of
terms to merge with
“We’ve now seen benefit in Neonorm™, as well as in our drug
and drug product candidates at Napo and Jaguar—Mytesi™ and
Canalevia™, respectively,” commented
Mytesi™ (crofelemer 125mg delayed-release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi™ is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi™. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). Please see complete Prescribing Information available at Mytesi.com
For more information, please visit www.jaguaranimalhealth.com.
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s plans to launch the prophylactic formulation of Neonorm Calf this year in powder form for administration in liquid, the Company’s intention to develop formulations of SB-300 in horses and species-specific formulations of Neonorm™ in additional target species, and the Company’s plan to develop formulations of Canalevia™ for cats and dogs. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
1Diarrhoea or Scour. Retrieved
View source version on businesswire.com: http://www.businesswire.com/news/home/20170214005536/en/
KCSA Strategic Communications
Garth Russell, 212-896-1250